Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00004195" target="_blank" >RIV/61989592:15110/07:00004195 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Original language description

Cyclosporin A is a well-known calcineurin inhibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this stud was to evaluate the eflicacy and safety of a new genetic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant recipients. Methods:Twenty cadaveric-donor renal transplant recipients between 23 abd 71 years of age at the tie of transplantation (mean age 52+-12,5 years) wete folkowed for 12 montis to determie if the gratts functioned and ion there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and Prednisone (Prednison). Results. Mean serum creatinine level decreased significantly after transplantation. in 6 of the 20 patients observed. 7 biopsies showed acute rejection episodes (35%) Over the 12-month post-transplant periodm,´, all patients showed stable graft function, with a mean serum creatinine level of 202

Czech name

Efficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidnex Transplantation

Czech description

Cyclosporin A is a well-known calcineurin inhibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this stud was to evaluate the eflicacy and safety of a new genetic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant recipients. Methods:Twenty cadaveric-donor renal transplant recipients between 23 abd 71 years of age at the tie of transplantation (mean age 52+-12,5 years) wete folkowed for 12 montis to determie if the gratts functioned and ion there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and Prednisone (Prednison). Results. Mean serum creatinine level decreased significantly after transplantation. in 6 of the 20 patients observed. 7 biopsies showed acute rejection episodes (35%) Over the 12-month post-transplant periodm,´, all patients showed stable graft function, with a mean serum creatinine level of 202

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FJ - Surgery including transplantology

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2007

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Transplantation

ISSN

0041-1337

e-ISSN

—

Volume of the periodical

36

Issue of the periodical within the volume

11

Country of publishing house

US - UNITED STATES

Number of pages

6

Pages from-to

602-607

UT code for WoS article

—

EID of the result in the Scopus database

—